Gemzar (gemcitabine HCL)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved August 1998

Specific Treatments:

Lung cancer

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Gemzar is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. It is also indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU.

Side Effects

Prolongation of the infusion time beyond 60 minutes and more frequent than weekly doses have been shown to increase toxicity. Gemzar can surpress bone marrow function as manifested by leukopenia, thrombocytopenia and anemia. Patients should also be monitores for myelosurpression during therapy. Gemzar can also cause fetal harm when administered to a pregnant woman.